Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study

Trial Profile

Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Raltegravir (Primary) ; Lamivudine/zidovudine; Lopinavir/ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2017 Planned End Date changed from 1 Mar 2016 to 1 Jul 2017.
    • 22 Feb 2017 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2017.
    • 05 Mar 2015 Planned End Date changed from 1 May 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top